Pfizer Says Lipitor Buyers Can't Bring Antitrust Challenge

Law360, New York (November 19, 2012, 4:36 PM EST) -- Pfizer Inc. sought Friday to end a class action concerning its purportedly anti-competitive settlement resolving patent litigation over Ranbaxy Inc.'s generic challenge to Pfizer's cholesterol drug Lipitor, telling a New Jersey federal court that the drug retailer plaintiffs lack standing to pursue the case.

In a bid for dismissal of claims brought by a group of direct purchaser plaintiffs in the larger multidistrict litigation against Pfizer, Ranbaxy and others, the Lipitor maker took issue with the direct purchasers' right to bring an antitrust suit when they...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.